Compare Solaredge Technologies Inc (SEDG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs BIO-TECHNE Corp — how do they compare? Solaredge Technologies Inc trades at $33.31 (market cap $1.98B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 5.7× Solaredge Technologies Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| SEDG | TECH | |
|---|---|---|
Market Cap | $1.98B | $11.24B |
Sector | Technology | Health |
52-Week High | $78.51 | $72.29 |
52-Week Low | $24.90 | $43.31 |
Enterprise Value | $1.84B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $31.76, down 2.79% amid weak Q3 2026 revenue guidance overshadowing a Q2 earnings beat. The stock exhibits a bearish technical trend with key support at $30 and resistance at $34. Fundamentally, the company reported a net loss of $405.45 million in 2025, though revenue grew to $1.18 billion, with profitability metrics like ROE at -58.42% reflecting ongoing challenges in the residential solar market.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus suggests a potential upside to $35.15. Key risks include soft U.S. demand and execution hurdles, while institutional sentiment is mixed with 20.83% buy ratings. Investors should weigh cost-control progress against macroeconomic headwinds in the solar sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
